SA
Sign upLog In
ARWR

ARWR R&D Expenses

$723.37MTTM · USD

Period ending:

QuarterlyTTMAnnualChart Studio →
ARWR FY R&D ExpensesUSD
ARWR FY R&D Expenses1997-09-30: $0.001998-09-30: $0.001999-09-30: $0.002000-09-30: $0.002001-09-30: $0.002002-09-30: $0.002003-09-30: $3.38K2004-09-30: $793.35K2005-09-30: $3.79M2006-09-30: $8.58M2007-09-30: $10.94M2008-09-30: $8.31M2009-09-30: $6.21M2010-09-30: $857.41K2011-09-30: $3.28M2012-09-30: $5.39M2013-09-30: $8.71M2014-09-30: $23.14M2015-09-30: $47.27M2016-09-30: $41.45M2017-09-30: $46.25M2018-09-30: $48.30M2019-09-30: $76.63M2020-09-30: $123.54M2021-09-30: $206.34M2022-09-30: $288.50M2023-09-30: $342.31M2024-09-30: $489.22M2025-09-30: $607.16M$607.16M$0.00
1997-09-302025-09-30

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

ARWR r&d expenses history

Research and development spending. The available annual fiscal periods series contains 29 observations from Sep 30, 1997 to Sep 30, 2025.

Arrowhead Pharmaceuticals Inc R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
607,159,000
489,216,000
342,312,000
288,500,000
206,342,000
123,543,716
76,628,541
48,296,230
46,252,027
41,454,452
47,267,361
23,138,050
8,705,627
5,391,463
3,277,760
857,409
6,207,157
8,309,556
10,935,643
8,582,019
3,793,377
793,354
3,375
0
0
0
0
0
0

Compare r&d expenses

All ARWR financial metrics · ARWR stock overview · How to interpret financial metrics

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.